admin

Oxular Initiates OXEYE Phase 2 Clinical Trial

Oxular is proud to announce it has begun dosing in its OXEYE for diabetic macular edema (DME), a common retinal disorder with high treatment burden. In OXEYE, we are delivering Oxular’s suprachoroidal OXU-001, our sustained release microsphere formulation of dexamethasone, via Oxulumis®, our posterior suprachoroidal microcatheter delivery device, with an aim to provide a safe and …

Oxular Initiates OXEYE Phase 2 Clinical Trial Read More »

Oxular appoints Mark Gaffney as CEO

As we transition to mid-stage development with our #ophthalmic pipeline and platform, and look to optimize the application of our technologies, Mark Gaffney’s decades of experience in corporate and financing strategy, business development and operations will be invaluable to Oxular’s future growth Oxular Announces Appointment of Mark Gaffney as Chief Executive Officer | Business Wire

Chris Verbicky – VP of GMP Drug Manufacturing

Chris is Oxular’s Vice President of GMP Drug Manufacturing, with more than 25 years of industry experience, Chris’s experience spans chemistry, manufacturing, and manufacturing controls, pilot-to-full scale production project management in both APIs and finished product, alliance management, injectable product development, formulation development, process development and scale-up, and licensing and partnering. He has also authored or contributed to over 70 patents, publications, and presentations concerning project management, business, and pharmaceutical development. Chris received a BS in Chemistry and an MBA from the University of Albany, USA, and holds a PhD in Synthetic Organic Chemistry from the University of New Hampshire, USA.

Pamela Lapham – Sr Director of Regulatory

Pamela is Oxular’s Senior Director of Regulatory Affairs, with over 30 years of experience working in all aspects of regulatory strategy and submissions. Previously, Pamela managed and coordinated regulatory efforts at Genocea, ProMedDx and Ximedica. She has significant experience in regulatory development, strategy, and filings and brings technical experience in clinical trials design, chemistry, manufacturing, …

Pamela Lapham – Sr Director of Regulatory Read More »

Ronald Yamamoto Chief Scientific Officer

Ronald is co-founder, Chief Scientific Officer, and a Board Observer of Oxular. With more than 30 years of medical device and drug product development experience, Ronald has led multi-disciplinary technical teams, clinical trial development, and product registration in the US, the EU, China, and Brazil. His ophthalmic experience includes the development of novel microcatheters for …

Ronald Yamamoto Chief Scientific Officer Read More »

Ian Anderson – Chief Technical Officer

Ian is Oxular’s Chief Technical Officer. He has significant experience in all technical aspects of medical device development and high-volume medical product industrialization. Ian journeyed from aeronautical and broadcast engineering into medical technologies, where he has been involved in the design, development, and launch of products as varied as surgical robots, auto-injector combination solutions, and stoma …

Ian Anderson – Chief Technical Officer Read More »

Dr. Dmitrij Hristodorov Director

Dmitrij is Partner at Forbion where, as a core member of the investment team, he contributes to investments across various stages, treatment modalities and diseases. Previously, he was Senior Director of Global Business Development & Licensing at Bayer Pharma, where he was responsible for ophthalmology, cardiology, nephrology, and pulmonology. Dmitrij currently serves as a board …

Dr. Dmitrij Hristodorov Director Read More »

Dr. Sam Williams

Sam has over 30 years’ experience in the Life Sciences sector as a scientist, company CEO and investment manager. He is currently Managing Partner at IP Group plc., the FTSE 250 investor, where he oversees the group’s c.£500m Life Sciences portfolio. He is founding CEO and Chairman of Istesso Ltd, a Phase 2 drug-discovery company, …

Dr. Sam Williams Read More »

Dr. Friedrich Asmus Chief Medical Officer

Friedrich, a board-certified neurologist and pharmacist is Oxular’s Chief Medical Officer and has over 20 years of experience in leading clinical and translational research in industry and academia. For more than a decade he has successfully headed clinical development programs in the US, Europe, and Asia. Friedrich was previously a key strategic contributor for retinal anti‑VEGF …

Dr. Friedrich Asmus Chief Medical Officer Read More »

David Fellows – Interim Chief Executive Officer

David is the Interim Chief Executive Officer of Oxular and has more than 30 years of experience in various leadership roles within the ophthalmic pharmaceutical industry. He was previously Chief Executive Officer of Nightstar Therapeutics, a private biopharmaceutical company specialising in developing ocular gene therapies for patients with inherited retinal dystrophies, with David leading the …

David Fellows – Interim Chief Executive Officer Read More »

Scroll to Top